Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21831279 | 0.88 | SLC6A3 (0.40) | OPRD1SLC6A3MGLLSIGMAR1 | |
| SCHEMBL21831116 | 0.88 | TSHR (0.48) | OPRD1SLC6A3SLC6A4 | |
| SCHEMBL21831198 | 0.86 | SIGMAR1 (0.37) | OPRD1MGLLSIGMAR1 | |
| SCHEMBL21831009 | 0.84 | OPRD1 (0.39) | OPRD1SIGMAR1 | |
| SCHEMBL21831825 | 0.84 | DPP4 (0.35) | OPRD1SLC6A3SLC6A4 | |
| SCHEMBL15093991 | 0.83 | MGLL (0.39) | SLC6A3MGLLSLC6A4SIGMAR1 | |
| SCHEMBL21831317 | 0.83 | FPR2 (0.42) | OPRD1SIGMAR1ALDH1A1 | |
| SCHEMBL21910157 | 0.82 | OPRD1 (0.35) | OPRD1MGLLMAPT | |
| SCHEMBL21831143 | 0.81 | PKM (0.39) | MGLL | |
| SCHEMBL25881972 | 0.80 | TSHR (0.50) | SLC6A3MGLLSLC6A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583876-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | Juno Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024054944-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | JUNO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4301755-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | Juno Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230089255-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-03-23 | — | — | US | disclosed |
| EP-4076529-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022187406-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2021127554-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112654621-A | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | OPRD1 2019/4885SLC6A3 4255/4885MGLL 2282/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | OPRD1 2019/4885SLC6A3 4255/4885MGLL 2282/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | OPRD1 2019/4885SLC6A3 4255/4885MGLL 2282/4885 |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | DGKG, DGKA, DGKI | OPRD1 4448/4885SLC6A3 4849/4885MGLL 297/4885 |
| US-20230089255-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | DGKA, DGKG, DGKB | OPRD1 4285/4885SLC6A3 4499/4885MGLL 65/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | OPRD1 2019/4885SLC6A3 4255/4885MGLL 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.